Company profile
Filana Therapeutics, Inc.
NASDAQ: FLNA · Healthcare · Biotechnology
#461 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
42DFH 36DQ 33GM 67SS 59
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), 3-yr revenue growth · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$91.0M
Employees
19
as of 2026-08-19
Market cap
$41.9M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$41.1M$41.1M2013
Net income-$91.0M-$91.0M2025
Operating income-$95.4M-$95.4M2025
Total assets$118.4M$118.4M2025
Liabilities$44.0M$44.0M2025
Equity$74.4M$74.4M2025
Revenue trend
FY2012 – FY2013 · USD
FY12
FY12
FY12
FY12
FY13
FY13
FY13
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Filana Therapeutics, Inc.’s revenue?
Filana Therapeutics, Inc. booked $41.1M in FY2013 revenue, growing 2000% year over year — faster than 97% of Healthcare companies we track, at a -221.2% net margin.
Peers · Healthcare
Biofrontera Inc.46DSelectis Health, Inc.60CKORU Medical Systems, Inc.72BEquillium, Inc.44DMyomo, Inc.53DEditas Medicine, Inc.45DNeighbors
Travis →Key facts
CEORichard Jon Barry
SectorHealthcare
IndustryBiotechnology
HeadquartersAustin, TX
ExchangeNASDAQ: FLNA
Employees19
IPO date2000-07-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.